Statement of Changes in Beneficial Ownership (4)

Date : 05/19/2017 @ 10:58AM
Source : Edgar (US Regulatory)
Stock : Endonovo Therapeutics, Inc. (QB) (ENDV)
Quote : 0.0556  0.0086 (18.30%) @ 4:00PM

Statement of Changes in Beneficial Ownership (4)

FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Mann Michael Scott
2. Issuer Name and Ticker or Trading Symbol

ENDONOVO THERAPEUTICS, INC. [ ENDV ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
President
(Last)          (First)          (Middle)

6320 CANOGA AVENUE
3. Date of Earliest Transaction (MM/DD/YYYY)

5/17/2017
(Street)

WOODLAND HILLS, CA 91367
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   5/17/2017     P    1000   A $0.0619   20829949   D    
Common Stock   5/17/2017     P    1000   A $0.0616   20830949   D    
Common Stock   5/17/2017     P    1000   A $0.0619   20831949   D    
Common Stock   5/17/2017     P    1000   A $0.059   20832949   D    
Common Stock   5/17/2017     P    1000   A $0.059   20833949   D    
Common Stock   5/17/2017     P    1000   A $0.06   20834949   D    
Common Stock   5/17/2017     P    1000   A $0.06   20835949   D    
Common Stock   5/17/2017     P    1000   A $0.06   20836949   D    
Common Stock   5/17/2017     P    1000   A $0.0599   20837949   D    
Common Stock   5/17/2017     P    1000   A $0.06   20838949   D    
Common Stock   5/17/2017     P    1000   A $0.0599   20839949   D    
Common Stock   5/17/2017     P    1000   A $0.06   20840949   D    
Common Stock   5/17/2017     P    1000   A $0.06   20841949   D    
Common Stock   5/17/2017     P    1000   A $0.06   20842949   D    
Common Stock   5/17/2017     P    1000   A $0.0577   20843949   D    
Common Stock   5/17/2017     P    1000   A $0.058   20844949   D    
Common Stock   5/17/2017     P    1000   A $0.058   20845949   D    
Common Stock   5/17/2017     P    1000   A $0.058   20846949   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Mann Michael Scott
6320 CANOGA AVENUE
WOODLAND HILLS, CA 91367

X President

Signatures
Michael Mann 5/19/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Endonovo Therapeutics, Inc. (USOTC:ENDV)
Historical Stock Chart

1 Year : From Jun 2016 to Jun 2017

Click Here for more Endonovo Therapeutics, Inc. Charts.

Endonovo Therapeutics, Inc. (USOTC:ENDV)
Intraday Stock Chart

Today : Friday 23 June 2017

Click Here for more Endonovo Therapeutics, Inc. Charts.

Latest ENDV Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.